Nivolumab Subcutaneous
Sponsors
Bristol-Myers Squibb Services Unlimited Company, Bristol Myers Squibb International Corporation
Conditions
Advanced Solid TumorsMelanomaMetastatic Clear Cell Renal Cell CarcinomaNon-small cell lung cancer (NSCLC)lung cancer; kidney cancer; melanoma; liver cancer; colorectal cancer; bladder cancer
Phase 1
CA209-8KX Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy
CompletedCTIS2023-503554-12-00
Start: 2019-01-09End: 2024-09-12Target: 96Updated: 2024-07-19
A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants with Advanced Solid Tumors
RecruitingCTIS2024-516602-28-00
Start: 2025-11-21Target: 62Updated: 2026-01-19
Phase 2
A Phase 2 Open-label, Two-cohort Study to Evaluate Patient Preference for nivolumab + relatlimab Fixed-dose Combination Subcutaneous versus nivolumab + relatlimab Fixed-dose Combination Intravenous and nivolumab Subcutaneous versus nivolumab Intravenous in Participants with Melanoma
Active, not recruitingCTIS2023-504515-33-00
Start: 2024-02-19Target: 82Updated: 2026-01-05
A Phase 2, Open-label, Randomized Trial to Evaluate Two Dosing Regimens of Subcutaneous Formulation of Nivolumab in Combination with Intravenous Ipilimumab and Chemotherapy in Participants with Previously Untreated Metastatic or Recurrent NSCLC (CheckMate-1533)
RecruitingCTIS2024-520108-25-00
Start: 2025-09-18Target: 40Updated: 2025-09-04